Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ('Inhibikase” or 'Company”), a clinical-stage pharmaceutical company developing ...

Falls and other non-dopaminergic symptoms in Parkinson’s disease remain a significant unmet need, with limited effective ...

KERENDIA is a non-steroidal mineralocorticoid receptor antagonist (nsMRA) that selectively and potently blocks mineralocorticoid receptor overactivation in the heart and kidneys. 2 FIND-CKD is the ...

Shares of Xenon Pharmaceuticals (XENE) have gained approximately 20% over the past three months, primarily driven by positive ...

Structure Therapeutics' Phase 2 data for Aleniglipron show 16% weight loss at 44 weeks with strong tolerability and no safety ...

Altimmune (NASDAQ:ALT) executives highlighted clinical progress across multiple pemvidutide programs and discussed the ...

Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported ...

BACKGROUND: Premature atrial contractions (PACs) are independently associated with atrial fibrillation, stroke, and heart ...

Following End-of-Phase 2 meeting, MBX remains on track to initiate Phase 3 in Q3 2026CARMEL, Ind., March 09, 2026 (GLOBE ...

Following End-of-Phase 2 meeting, MBX remains on track to initiate Phase 3 in Q3 2026In the fourth paragraph, we are replacing milligrams with micrograms. The corrected press release follows. CARMEL, ...

Figure 1: a, Genomic structures of HIV–1 and SHIVs used here. Although the clearance values measured in the three assays differed somewhat, they were all in a range similar to that reported for the ...